Cite this: Technology Insight: ECP for the treatment of GvHD-Can We Offer Selective Immune Control Without Generalized Immunosuppression? - Medscape - Jun 01, 2006. SR Marshall is a specialist ...

Please provide your email address to receive an email when new articles are posted on . “It really does fit earlier in the treatment paradigm and later in the treatment paradigm, making ECP a still ...

Endoscopic cyclophotocoagulation had better effect at early stages and ultrasound cycloplasty had higher safety and tolerance when treating intraocular pressure (IOP) in patients with secondary ...

N4 Pharma plc’s subsidiary Nanogenics Ltd. has signed a contract to start the formulation and sequence selection work to prepare its ECP-105 product for testing in preclinical studies at King’s ...

Westbury, NY (Vocus) October 21, 2010-- Vasomedical, Inc. (“ Vasomedical”) (OTC: VASO.OB), a world leader in the noninvasive treatment of cardiovascular diseases, today announced the online ...